Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients.

Next Previous
Trial Profile

A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Methylnaltrexone bromide (Primary)
  • Indications Constipation
  • Focus Therapeutic Use
  • Sponsors Bausch Health Companies; Progenics Pharmaceuticals

Most Recent Events

  • 22 Dec 2021 According to Bausch Health Companies media release, results assessing safety and efficacy of a single methylnaltrexone dose using post hoc polled data from 3 trials (study 301, NCT00401362; study 302, NCT00402038; and study 4000, NCT00672477) published in The Journal of Emergency Medicine
  • 22 Dec 2021 Results assessing safety and efficacy of a single methylnaltrexone dose using post hoc polled data from 3 trials (study 301, NCT00401362; study 302, NCT00402038; and study 4000, NCT00672477) published in the Bausch Health Companies Media Release
  • 22 Dec 2021 According to Bausch Health Companies media release, data from a post-hoc analysis (study 301, NCT00401362; study 302, NCT00402038; and study 4000, NCT00672477) supports the use of Salix s RELISTOR for patients with Opioid-Induced Constipation and advanced illness in the Emergency Department Setting

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top